Genta Incorporated announced that the European Patent Office intends to grant two key patents related to the company’s intellectual property position on Genasense® (oblimersen sodium) Injection. These two patents will provide protection for compositions, sequences, and pharmaceutical uses of Genasense and related compounds that attack Bcl-2, the molecular target of Genasense action.